The use of molecular volumetric parameters for the evaluation of Lu-177 PSMA I&T therapy response and survival

被引：0
|
作者：
Emine Acar
Özhan Özdoğan
Ayşegül Aksu
Erkan Derebek
Recep Bekiş
Gamze Çapa Kaya
机构：
[1] İzmir Kâtip Çelebi University,Department of Nuclear Medicine, Ataturk Training and Research Hospital
[2] Dokuz Eylul University,Department of Translational Oncology, Institute of Health Sciences
[3] Dokuz Eylul University,Department of Nuclear Medicine, School of Medicine
来源：
Annals of Nuclear Medicine | 2019年 / 33卷
关键词：
PSMA; MTV; TLG; Tumor volume; Precision medicine; Theranostic;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：681 / 688
页数：7
相关论文
共 38 条
  • [31] Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer
    Heck, Matthias M.
    Tauber, Robert
    Schwaiger, Sebastian
    Retz, Margitta
    D'Alessandria, Calogero
    Maurer, Tobias
    Gafita, Andrei
    Wester, Hans-Juergen
    Gschwend, Juergen E.
    Weber, Wolfgang A.
    Schwaiger, Markus
    Knorr, Karina
    Eiber, Matthias
    EUROPEAN UROLOGY, 2019, 75 (06) : 920 - 926
  • [32] Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand therapy
    Rosar, Florian
    Wenner, Felix
    Khreish, Fadi
    Dewes, Sebastian
    Wagenpfeil, Gudrun
    Hoffmann, Manuela A.
    Schreckenberger, Mathias
    Bartholoma, Mark
    Ezziddin, Samer
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (05) : 1584 - 1594
  • [33] Influence of dosimetry method on bone lesion absorbed dose estimates in PSMA therapy: application to mCRPC patients receiving Lu-177-PSMA-I&T (vol 8, 26, 2021)
    Brosch-Lenz, Julia
    Uribe, Carlos
    Gosewisch, Astrid
    Kaiser, Lena
    Todica, Andrei
    Ilhan, Harun
    Gildehaus, Franz Josef
    Bartenstein, Peter
    Rahmim, Arman
    Celler, Anna
    Ziegler, Sibylle
    Boening, Guido
    EJNMMI PHYSICS, 2021, 8 (01)
  • [34] Investigation of image-based lesion and kidney dosimetry protocols for 177Lu-PSMA-I&T therapy with and without a late SPECT/CT acquisition
    Resch, Sandra
    Fouladgar, Sarah Takayama
    Zacherl, Mathias
    Sheikh, Gabriel T. T.
    Liubchenko, Grigory
    Rumiantcev, Mikhail
    Unterrainer, Lena M. M.
    Wenter, Vera
    Bartenstein, Peter
    Ziegler, Sibylle I. I.
    Ilhan, Harun
    Beyer, Leonie
    Boening, Guido
    Delker, Astrid
    EJNMMI PHYSICS, 2023, 10 (01)
  • [35] Investigation of image-based lesion and kidney dosimetry protocols for 177Lu-PSMA-I&T therapy with and without a late SPECT/CT acquisition
    Sandra Resch
    Sarah Takayama Fouladgar
    Mathias Zacherl
    Gabriel T. Sheikh
    Grigory Liubchenko
    Mikhail Rumiantcev
    Lena M. Unterrainer
    Vera Wenter
    Peter Bartenstein
    Sibylle I. Ziegler
    Harun Ilhan
    Leonie Beyer
    Guido Böning
    Astrid Delker
    EJNMMI Physics, 10
  • [36] 225Ac-PSMA-617 Augmentation After Insufficient Response Under 177Lu-PSMA-617 Radioligand Therapy in mCRPC: Evaluation of Outcome and Safety From a Prospective Registry (REALITY Study)
    Rosar, Florian
    Khreish, Fadi
    Nagel, Lea Sophie
    Blickle, Arne
    Burgard, Caroline
    Petto, Sven
    Bastian, Moritz B.
    Speicher, Tilman
    Bartholomae, Mark
    Maus, Stephan
    Schaefer-Schuler, Andrea
    Ezziddin, Samer
    CLINICAL NUCLEAR MEDICINE, 2025, 50 (04) : e202 - e206
  • [37] Analysis of Molecular Imaging Biomarkers Derived from [18F]FDG PET/CT in mCRPC: Whole-Body Total Lesion Glycolysis (TLG) Predicts Overall Survival in Patients Undergoing [225Ac]Ac-PSMA-617-Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy
    Burgard, Caroline
    Khreish, Fadi
    Dahlmanns, Lukas
    Blickle, Arne
    Bastian, Moritz B.
    Speicher, Tilman
    Maus, Stephan
    Schaefer-Schuler, Andrea
    Bartholomae, Mark
    Petto, Sven
    Ezziddin, Samer
    Rosar, Florian
    CANCERS, 2024, 16 (20)
  • [38] In Comparison to PSA, Interim Ga-68-PSMA PET/CT Response Evaluation Based on Modified RECIST 1.1 After 2nd Cycle Is Better Predictor of Overall Survival of Prostate Cancer Patients Treated With 177Lu-PSMA
    Prasad, Vikas
    Huang, Kai
    Prasad, Sonal
    Makowski, Marcus R.
    Czech, Norbert
    Brenner, Winfried
    FRONTIERS IN ONCOLOGY, 2021, 11
1234